logo
Plus   Neg
Share
Email

Pfeiffer Vacuum Expects Q2 Results To Be Weaker

Pfeiffer Vacuum Technology AG (PFFVF.PK) said it expects sales to be in the range of around 140 million euros to 145 million euros in the second quarter 2020 ending June 30, 2020, compared to 157.4 million euros reported last year. The decline is primarily driven by the decrease in demand due to global economic conditions, partially offset by continued strong demand in the semiconductor market.

The operating result (EBIT) is expected to be in the range of 3.0 million euros to 6.5 million euros, significantly lower than the previous year's 14.7 million euros. This is primary hurt by productivity loss due to sales declines and COVID-19
measures, product and market mix, and year-over-year increased expenses to drive market share growth.

The order intake in second quarter 2020 is expected to be at or slightly above last year's 144.9 million euros.

The company said it will announce detailed results for the second quarter and first
half 2020 on August 4, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Guitar Center Inc., a retailer of musical instruments, lessons, repairs and rentals, has filed for Chapter 11 bankruptcy reorganization, aiming to significantly reduce its debt and continue its business amid ongoing struggles following the coronavirus pandemic. The company, which operates nearly 300 stores across the U.S., expects to complete the process before the end of this year. Amazon is offering new "Spoiler Free" ways to keep gifts a surprise, as well as to track, receive and pick up orders this holiday season. According to the company, the new features would help customers to face the challenge of keeping those special gifts under wraps as many families are opting to stay home amid the coronavirus pandemic. AstraZeneca Plc and Oxford University's coronavirus vaccine candidate AZD1222 is found to be 70 percent effective on average against Covid-19, according to the British pharmaceutical giant. AstraZeneca plans to immediately prepare regulatory submission of the data to worldwide authorities for conditional or early approval. The company will also ask for an Emergency Use Listing from the WHO.
Follow RTT